Chronic kidney disease (CKD) affects 15% of US adults (37 million people), and its progression to end-stage renal disease (ESRD) has historically been managed with a narrow toolkit — ACE inhibitors/ARBs, blood pressure control, and dietary protein restriction. The 2020–2024 period has produced a paradigm shift with multiple large RCTs demonstrating that SGLT2 inhibitors, the non-steroidal mineralocorticoid receptor antagonist finerenone, and GLP-1 agonists produce additive renoprotection beyond the RAS inhibitor standard of care.
SGLT2 Inhibitors: The New Standard
DAPA-CKD (dapagliflozin, n=4,304): 44% reduction in composite kidney failure, sustained ≥50% eGFR decline, or renal/CV death — in both diabetic AND non-diabetic CKD patients (eGFR 25–75, uACR ≥200). The non-diabetic CKD benefit was unexpected and practice-changing. EMPA-KIDNEY (empagliflozin, n=6,609): 28% reduction in kidney disease progression or CV death — benefit seen even at very low eGFR (as low as 20 mL/min/1.73m²). Mechanism: beyond glucose effects, SGLT2 inhibitors reduce intraglomerular hypertension (tubuloglomerular feedback normalization), reduce inflammation and fibrosis, and improve mitochondrial function. ADA/KDIGO 2024 guidelines: SGLT2 inhibitors recommended for all patients with T2DM + CKD (eGFR ≥20) and increasingly for non-diabetic proteinuric CKD.
Finerenone and Combination Therapy
Finerenone (Kerendia) — non-steroidal MRA: FIDELIO-DKD (n=5,734) and FIGARO-DKD (n=7,437) showed 18–23% reduction in CKD progression and 14% reduction in CV events in CKD-T2DM. Unlike spironolactone/eplerenone, finerenone has high renal selectivity and lower hyperkalemia risk — enabling use in patients with CKD where aldosterone blockade was previously avoided. Pooled FIDELITY analysis: SGLT2i + finerenone combination shows additive cardiorenal protection — expected to become standard quadruple therapy (RAS inhibitor + SGLT2i + finerenone + GLP-1 agonist) for high-risk CKD-T2DM patients. For dialysis and nephrology facilities, our vascular access catalog includes dialysis access supplies, and our diagnostic equipment section includes urinalysis and kidney function monitoring tools.
